Genital Warts
39
1
4
32
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Published Results
15 trials with published results (38%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
2.6%
1 terminated out of 39 trials
97.0%
+10.4% vs benchmark
51%
20 trials in Phase 3/4
47%
15 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (39)
Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)